NASDAQ:FRLN

Freeline Therapeutics Stock Forecast, Price & News

$4.76
+0.01 (+0.21 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.72
$4.90
50-Day Range
$4.66
$11.00
52-Week Range
$4.26
$21.69
Volume143,017 shs
Average Volume444,382 shs
Market Capitalization$170.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FRLN News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Freeline Therapeutics logo

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.81 out of 5 stars

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Freeline Therapeutics (NASDAQ:FRLN) Frequently Asked Questions

Is Freeline Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Freeline Therapeutics stock.
View analyst ratings for Freeline Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Freeline Therapeutics?

Wall Street analysts have given Freeline Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Freeline Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Freeline Therapeutics?

Freeline Therapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 34,400 shares, a drop of 37.3% from the June 30th total of 54,900 shares. Based on an average trading volume of 136,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are short sold.
View Freeline Therapeutics' Short Interest
.

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) issued its quarterly earnings data on Sunday, May, 16th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.20.
View Freeline Therapeutics' earnings history
.

What price target have analysts set for FRLN?

9 equities research analysts have issued 1-year target prices for Freeline Therapeutics' shares. Their forecasts range from $17.00 to $30.00. On average, they anticipate Freeline Therapeutics' stock price to reach $24.57 in the next twelve months. This suggests a possible upside of 416.2% from the stock's current price.
View analysts' price targets for Freeline Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Freeline Therapeutics' key executives?

Freeline Therapeutics' management team includes the following people:
  • Ms. Theresa Marie Heggie, CEO & Director (Age 61)
  • Mr. Michael J. Parini, COO & Pres (Age 46)
  • Dr. Amit Nathwani M.D., Ph.D., Founder, Clinical & Scientific Adviser and Independent Director (Age 61)
  • Dr. Markus Horer Ph.D., Founder, CTO & Managing Director GmbH (Age 54)
  • Dr. Romuald Corbau Ph.D., Chief Scientific Officer (Age 52)
  • Mr. David S. Arrington, VP of Investor Relations & Corp. Communications
  • Mr. Stephen P. Diamond Jr., Sr. VP & Gen. Counsel (Age 49)
  • Dr. Jan Thirkettle Ph.D., Chief Devel. Officer (Age 49)
  • Mr. Eric Fink, Chief HR Officer (Age 44)
  • Dr. Gerard Short, Head of Clinical and Regulatory

Who are some of Freeline Therapeutics' key competitors?

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).

When did Freeline Therapeutics IPO?

(FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Freeline Therapeutics' stock symbol?

Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN."

How do I buy shares of Freeline Therapeutics?

Shares of FRLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Freeline Therapeutics' stock price today?

One share of FRLN stock can currently be purchased for approximately $4.76.

How much money does Freeline Therapeutics make?

Freeline Therapeutics has a market capitalization of $170.60 million. The company earns $-96,320,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis.

How many employees does Freeline Therapeutics have?

Freeline Therapeutics employs 236 workers across the globe.

What is Freeline Therapeutics' official website?

The official website for Freeline Therapeutics is www.freeline.life.

Where are Freeline Therapeutics' headquarters?

Freeline Therapeutics is headquartered at STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX.

How can I contact Freeline Therapeutics?

Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The company can be reached via phone at 44-14-3890-6870 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.